Ascendis Pharma A/S
ASND
Pozycja w akcjach
#1507
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Cena akcji
$230.45
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$14.37B
Zmiana (1 dzień)
2.31%
Zmiana (1 rok)
12.30%
Kraj
DK
Handel Ascendis Pharma A/S (ASND)
Kategoria
Healthcare
Zyski dla Ascendis Pharma A/S (ASND)
Zyski w Jun 2026 TTM: $119.93M
Według najnowszych raportów finansowych Ascendis Pharma A/S, obecny zysk firmy wynosi $119.93M. W roku 2024 firma osiągnęła zysk w wysokości $-388.38M, wzrost w porównaniu do zysku z roku 2023, który wynosił $-524.15M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Ascendis Pharma A/S od 2012 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $119.93M | -150.04% |
| 2025 | $-239.65M | -38.30% |
| 2024 | $-388.38M | -25.90% |
| 2023 | $-524.15M | -15.43% |
| 2022 | $-619.81M | 41.96% |
| 2021 | $-436.60M | -14.48% |
| 2020 | $-510.50M | 108.47% |
| 2019 | $-244.87M | 63.30% |
| 2018 | $-149.95M | 0.48% |
| 2017 | $-149.24M | 106.36% |
| 2016 | $-72.32M | 98.38% |
| 2015 | $-36.46M | 191.39% |
| 2014 | $-12.51M | -293.36% |
| 2013 | $6.47M | 281.71% |
| 2012 | $1.70M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | 4,298.37% |
US
|
|
| $-3.09B | -2,674.04% |
US
|
|
| $-4.02B | -3,448.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,526.51% |
NL
|
